Generic Name and Formulations:
Carisoprodol 350mg; tabs.
Mylan Specialty L.P.
Indications for SOMA:
Relief of acute, painful musculoskeletal conditions.
≥16yrs: 250mg–350mg 3 times daily and at bedtime. Max 2–3 weeks.
<16yrs: not recommended.
Renal or hepatic dysfunction. Drug abuse. Pregnancy (Cat.C). Nursing mothers.
Sedative effects potentiated by alcohol, other CNS depressants. May be potentiated by CYP2C19 inhibitors (eg, omeprazole, fluvoxamine). May be antagonized by CYP2C19 inducers (eg, rifampin, St. John's Wort).
Muscle relaxant (central).
Dizziness, drowsiness, headache, GI upset, rash, tachycardia, orthostatic hypotension; rare idiosyncratic reactions (see literature).
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics